Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent…
NCT00114218 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00114218 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer |
| Official title | A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma |
| Intervention type | Drug |
| Interventions | Gemcitabine Hydrochloride, Docetaxel |
| Enrollment | 28 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2010 |
| First posted | Jun 14, 2005 |
| Last update posted | Jan 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: